GT Biopharma reported FY 2025 results, ending the year with cash and cash equivalents of about USD 7 million and citing an unaudited proforma cash balance of about USD 9 million as of Jan. 31, 2026, which it expects to fund operations through Q4 2026. For FY 2025, R&D expenses were about USD 3.5 million (down 39.7%), primarily due to lower production and material costs, while SG&A expenses (excluding stock compensation) were about USD 8.5 million. Loss from operations was about USD 12.4 million (down 13.9%) and net loss was about USD 28.4 million (up 2.2x), driven mainly by a non-cash expense from changes in the fair value of additional investment rights tied to its Series L preferred stock. On the pipeline, GT Biopharma said its Phase 1 dose-escalation trial of GTB-3650 in relapsed/refractory CD33-expressing hematologic malignancies is actively enrolling, with Cohort 4 (10 µg/kg/day) ongoing and dosing in Cohort 5 (25 µg/kg/day) expected to start in Q2 2026; the next trial update is anticipated in Q3 2026 following completion of enrollment in Cohort 5. The company also said it remains on track to initiate a Phase 1 basket trial of GTB-5550 in B7-H3-expressing solid tumors in mid-2026, following FDA IND clearance in late January 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603020700PRIMZONEFULLFEED9663752) on March 02, 2026, and is solely responsible for the information contained therein.